[{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Approved FDF","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Pharma \/ 4D Pharma","highestDevelopmentStatusID":"15","companyTruncated":"4D Pharma \/ 4D Pharma"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Avelumab","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Blautia Hydrogenotrophica","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Merck & Co"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"MRx0518","moa":"Toll-like-5 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"MRx-4DP0004","moa":"Dendritic cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"MRx0005","moa":"IL-6 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"4D Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"4D Pharma \/ Inapplicable"},{"orgOrder":0,"company":"4D Pharma","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"||Toll-like-5 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"4D Pharma \/ 4D Pharma","highestDevelopmentStatusID":"4","companyTruncated":"4D Pharma \/ 4D Pharma"},{"orgOrder":0,"company":"4D Pharma","sponsor":"LabCorp | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MRx0029","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"4D Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4D Pharma \/ LabCorp | Icon Plc","highestDevelopmentStatusID":"6","companyTruncated":"4D Pharma \/ LabCorp | Icon Plc"}]
Find Clinical Drug Pipeline Developments & Deals by 4D Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
